Introducing a new “OvaView” summary featuring Victoria Haverbusch, our expert in risk assessment. Explore the latest advancements in biomarker technology for assessing ovarian cancer risk in a concise video and gain valuable insights to enrich your clinical decision-making process.

In honor of World Ovarian Cancer Day, Aspira Women’s Health CEO Nicole Sandford and WOCC CEO Clara MacKay discuss the crucial role of awareness and early detection in ovarian cancer.

Presentation at the NeauxCancer Conference 2024 discussing investment strategies.

Aspira’s CEO, Nicole Sandford, SVP, Michelle Snider, and Sales Rep. & Patient, Lottie Wilder, were interviewed to discuss Aspira’s commercial refresh, what’s ahead for the company, and Lottie’s personal health journey.

Aspira’s CEO, Nicole Sandford, and Clinical Advisory Board member, Dr. Tamika Sea MD, FACOG, were interviewed to discuss the establishment of Aspira’s Clinical Advisory Board, an element of its overall mission to develop and distribute high-impact diagnostic tools for gynecologic disease.

During the interview, Nicole and Sally discussed updates on clinical interest in Aspira’s ovarian cancer risk assessment tests after the publication of three abstracts at the recent ASCO meeting, the use of OvaWatchSin serial monitoring of patients with adnexal masses that change over time, and the commercial availability of EndoCheck, the diagnostic test for endometriosis.

Aspira’s CEO, Nicole Sandford, talked with Jane King of New to The Street about ovarian cancer and how Aspira is advancing ovarian cancer risk assessment with advanced bioinformatics and noninvasive blood tests.

Aspira Women’s Health CEO, Nicole Sandford, talks about OvaWatch test as well as her own personal journey with an adnexal mass; and, expert in the field of gynecology, Dr. Gerard Reilly, explains the importance of early detection and how he uses this test in his practice.